This document discusses diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), which are diabetes emergencies. DKA is characterized by ketosis and acidosis, while HHS features extreme hyperglycemia and dehydration. Risk factors include new diabetes diagnosis, infection, and drug use. Clinical presentation of DKA includes hyperglycemic symptoms and ketosis, while HHS presents with profound dehydration and neurological issues. Treatment objectives are rehydration, resolving acidosis, correcting electrolytes, treating hyperglycemia, and identifying underlying causes. Complications can be fatal, especially within the first few days.
This document discusses diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), which are diabetes emergencies. DKA is characterized by ketosis and acidosis, while HHS features extreme hyperglycemia and dehydration. Risk factors include new diabetes diagnosis, infection, and drug use. Clinical presentation of DKA includes hyperglycemic symptoms and ketosis, while HHS presents with profound dehydration and neurological issues. Treatment objectives are rehydration, resolving acidosis, correcting electrolytes, treating hyperglycemia, and identifying underlying causes. Complications can be fatal, especially within the first few days.
This document discusses diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), which are diabetes emergencies. DKA is characterized by ketosis and acidosis, while HHS features extreme hyperglycemia and dehydration. Risk factors include new diabetes diagnosis, infection, and drug use. Clinical presentation of DKA includes hyperglycemic symptoms and ketosis, while HHS presents with profound dehydration and neurological issues. Treatment objectives are rehydration, resolving acidosis, correcting electrolytes, treating hyperglycemia, and identifying underlying causes. Complications can be fatal, especially within the first few days.
This document discusses diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), which are diabetes emergencies. DKA is characterized by ketosis and acidosis, while HHS features extreme hyperglycemia and dehydration. Risk factors include new diabetes diagnosis, infection, and drug use. Clinical presentation of DKA includes hyperglycemic symptoms and ketosis, while HHS presents with profound dehydration and neurological issues. Treatment objectives are rehydration, resolving acidosis, correcting electrolytes, treating hyperglycemia, and identifying underlying causes. Complications can be fatal, especially within the first few days.
Download as PPTX, PDF, TXT or read online from Scribd
Download as pptx, pdf, or txt
You are on page 1of 21
YUDO PRABOWO
Canadian Diabetes Association Clinical Practice
Guidline Expert Committe 2013 Introduction Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemicstate (HHS) are diabetes emergencies with overlapping features. DKA : Potassium is shifted out of cells, and ketoacidosis occurs as a result of elevated glucagon levels and absolute insulin deciency (DMTI) high catecholamine levels suppressing insulin release (DMTII) Ketoacidosis prominent Cont. HHS : the main features are ECFV depletion and hyperosmolarity hyperglycemia causes urinary losses of water and electrolytes (sodium, potassium, chloride) Risk Factor DKA HHS new diagnosis of diabetes Same as DKA mellitus also has been reported insulin omission following cardiac surgery Infection use of certain drugs, myocardial infarction including diuretics, glucocorticoids, lithium and abdominal crisis atypical antipsychotics trauma treatment with insulin infusion pumps thyrotoxicosis cocaine, atypical antipsychotics and interferon. clinical presentation DKA HHS symptoms of often more profound hyperglycemia ECFV contraction Kussmaul respiration decreased level of acetone-odoured breath consciousness ECFV contraction (proportional to the elevation in plasma nausea osmolality). vomiting variety of neurological abdominal pain presentations, including decreased level of seizures and a stroke-like consciousness state resolve once osmolality returns to normal Diagnosis DKA or HHS should be suspected whenever patients have signicant hyperglycemia, especially if they are ill or highly symptomatic.
to make the diagnosis and determine the severity of DKA or
HHS, the following should be assessed: plasma levels of electrolytes (and anion gap) glucose, creatinine, osmolality beta-hydroxybutyric acid (beta-OHB) (if available) Blood gases Serum and urine ketones uidbalance level of consciousness, precipitating factors and complications Cont. There are no denitive HHS: criteria for the diagnosis higher glucose levels of DKA. (typically 34.0 Typically, the arterial pH is mmol/L)( 612 mg/dl) 7.3 greater ECFV contraction serum bicarbonate is 15 minimal acid-base mmol/L disturbance anion gap is >12 mmol/L with positive serum and/or urine ketones. Plasma glucose is usually 14.0 mmol/L but can be lower ( 252 mg/dl) Management Objectives of management of DKA and HHS include restoration of normal ECFV tissue perfusion;
resolution of ketoacidosis;
correction of electrolyte imbalances and
hyperglycemia; and the
diagnosis and treatment of coexistent illness.
Cont. ECFV contraction ECFV re-expansion, using a rapid rate of initial uid administration, was associated with an increased risk of cerebral edema (CE) in 1 study but not in another. In adults, one should initially administer intravenous (IV) normal saline 1 to 2 L/h to correct shock, otherwise 500 mL/h for 4 hours, then 250 mL/h of IV uids Cont. Potassium decit Typical recommendations suggest that potassium supplementation should be started for plasma potassium <5.0 to 5.5 mmol/L once diuresis has been established, usually with the second litre of saline. If the patient at presentation is normo- or hypokalemic, potassium should be given immediately, at concentrations in the IV uid between 10 and 40 mmol/L, at a maximum rate of 40 mmol/h. Cont. Metabolic acidosis Insulin is used to stop ketoacid production; IV uid alone has no impact on parameters of ketoacidosis. Shor acting insulin (0.1 U/kg/h) is recommended initial bolus of IV insulin is recommended in some reviews Cont. there has been only 1 randomized controlled trial (RCT) in adults examining the effectiveness of this step. In this study, there were 3 arms: a bolus arm (0.07 units/kg, then 0.07 units/kg/h), a low-dose infusion group (no bolus, 0.07 units/kg/h), double-dose infusion group (no bolus, 0.14 units/kg/h).
Outcomes were identical in the 3 groups, except 5 of 12
patients needed extra insulin in the no-bolus/low-dose infusion group, and the double dose group had the lowest potassium . Unfortunately, this study did not examine the standard dose of insulin in DKA (0.1 units/kg/h). Cont The use of subcutaneous boluses of rapid-acting insulin analogues at 1- to 2-hour intervals results in similar duration of ketoacidosis with no more frequent occurrence of hypoglycemia compared to short-acting IV insulin 0.1 U/kg/h
Once plasma glucose reaches 14.0 mmol/L, IV
glucose should be started to prevent hypoglycemia, targeting a plasma glucose of 12.0 to 14.0 mmol/L Cont Use of IV sodium bicarbonate to treat acidosis did not affect outcome in RCTs. Sodium bicarbonate therapy can be considered in adult patients in shock or with arterial pH 7.0 1 amp sodium bicarbonate added to 200ml D5W/ 1hour, repeat 1- 2 hours until ph 7.
Potential risks associated with the use of sodium
bicarbonate include hypokalemia and delayed occurrence of metabolic alkalosis Hyperosmolality Hyperosmolality is due to hyperglycemia and a water decit. Because of the risk of CE with rapid reductions in osmolality, it has been recommended that the plasma osmolality be lowered no faster than 3 mmol/kg/h adding glucose to the infusions when plasma glucose reaches 14.0 mmol/L to maintain it at that level and by selecting the correct concentration of IV saline Phosphate deciency Thereis currently no evidence to support the use of phosphate therapy for DKA
thereis no evidence that hypophosphatemia causes
rhabdomyolysis in DKA hypophosphatemia has been associated with rhabdo myolysis in other states, administration of potassium phosphate in cases of severe hypophosphatemia may be considered for the purpose of trying to prevent rhabdomyolysis Complications In Ontario, in-hospital mortality in patients hospitalized for acute hyperglycemia ranged from<1% at ages 20 to 49 years to 16% in those over 75 years.
mortality in DKA ranges from 0.65% to 3.3%
HHS, recent studies found mortality rates to be 12% to 17%, but included patients with mixed DKA and hyperosmolality 50% of deaths occur in the rst 48 to 72 hours due to the precipitating cause, electrolyte imbalances (especially hypo- and hyperkalemia) and CE THANK YOU